SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Clinician reference, evidence review

CJC-1295

GHRH analog

Growth hormone releasing hormone analog, research grade, not FDA approved

Reviewed by: Sabrina Runbeck, PA-C, MHS, MPH, Co-Founder, Scriptura Health. Physician assistant, public health master's, health sciences master's. Sabrina reviews the clinical layer of Scriptura Health, and she reviews every compound reference on this site.

Published: 2026-07-08. This page is an evidence review, not clinical instruction, and does not recommend dosing, cadence, routes, or prescribing decisions. Prescribing is the responsibility of a licensed clinician evaluating a specific patient.

Regulatory posture

CJC-1295 is not FDA approved for any indication and has no marketing authorization in the United States. It is not an established compounding candidate and has been grouped among peptides that lack adequate safety and quality characterization for compounding. It is not scheduled by the DEA, but it is prohibited in sport by the World Anti-Doping Agency.

Mechanism, plain English

CJC-1295 is a synthetic copy of growth hormone releasing hormone, the natural signal that tells the pituitary gland to release growth hormone. Some versions are chemically modified to last longer in the body so the signal continues over time. By prompting more growth hormone release, it also raises insulin-like growth factor 1, a related hormone involved in growth and repair.

Evidence landscape

Human data on CJC-1295 are sparse and mostly limited to early pharmacology studies rather than outcome trials. A randomized study in healthy adults showed that CJC-1295 raised growth hormone and insulin-like growth factor 1 levels for an extended period, confirming its biological activity. Beyond this, there are no large trials establishing clinical benefit or long-term safety, and much of the available literature examines unregulated use and detection rather than therapeutic outcomes. A broader review of growth hormone secretagogues places CJC-1295 among agents with limited clinical evidence and cautions about the gap between marketing and data. Product quality and unregulated sourcing are recurring concerns in the literature.

Primary PubMed citations

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults , Teichman SL et al, Journal of Clinical Endocrinology and Metabolism, 2006. PMID: 16352683
  2. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions , Van Hout MC et al, Substance Use and Misuse, 2016. PMID: 26771670
  3. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males , Sinha DK et al, Translational Andrology and Urology, 2020. PMID: 32257855

Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.

Scope of this page

This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.

More clinician references

  • BPC-157 , Cytoprotective peptide, research grade, not FDA approved
  • TB-500 , Regenerative peptide, research grade, not FDA approved
  • Semaglutide , GLP-1 receptor agonist, FDA approved
  • Tirzepatide , Dual GIP and GLP-1 receptor agonist, FDA approved
  • Retatrutide , Triple GIP, GLP-1, and glucagon receptor agonist, investigational, not FDA approved
  • Ipamorelin , Growth hormone secretagogue, research grade, not FDA approved
  • Sermorelin , Growth hormone releasing hormone analog, research grade, not currently FDA marketed
  • Tesamorelin , Growth hormone releasing hormone analog, FDA approved
  • Thymosin Alpha-1 , Immunomodulatory peptide, not FDA approved in the US, orphan drug status

Want the evidence layer for your practice.

A daily one page regulatory brief and a plain English PubMed literature delta, in your Drive every morning. No prescribing, no dispensing, no pharmacy routing. Just the evidence and regulatory read a prescriber wants before writing the next protocol.

Book a demoRequest access
CJC-1295 clinician reference: evidence review and regulatory posture | Scriptura Health | Scriptura Health